ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferons and treatment"

  • Abstract Number: 770 • 2016 ACR/ARHP Annual Meeting

    Introducing a Novel SLE-Specific IFN-I Inhibitor CNTO 6358: Laying the Groundwork for Precision Medicine in Lupus

    Jarrat Jordan1, Matteo Cesaroni1, Jessica Schreiter1, Chichi Huang2, Tanesha Cash-Mason3, Marc Chevrier1 and Jacqueline Benson1, 1Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, 2Biologics Research, Janssen Research and Development, LLC., Spring House, PA, 3Cardiovascular and Metabolism Research, Janssen Research and Development, LLC., Spring House, PA

    Background/Purpose: The type I interferon (IFN-I) family of cytokines signal through a ubiquitously expressed heterodimeric receptor (IFNAR) composed of IFNAR1 and the high-affinity binding chain…
  • Abstract Number: 3229 • 2016 ACR/ARHP Annual Meeting

    Bone Morphogenetic Protein 6 Receptor Inhibition Restores Salivary Gland Function in a Mouse Model of Primary Sjögren’s Syndrome

    Hongen Yin1, Lovika Kalra1, Arif Karim1, Zhennan Lai1, Maria Guimaro1, Lauren Aber1, Bill Swaim1, Sandra Afione1, Alexandria Voigt2, Cuong Nguyen3, Paul Yu4, Donald Bloch5 and John A. Chiorini1, 1Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, 2Department of Pathology and Infectious Diseases, University of Florida, Gainesville, FL, 3Department of Pathology and Infectious Diseases, University of Florida, Bethesda, MD, 4Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 5Center for Immunology and Inflammatory Diseases and the Division of Rheumatology, Allergy, and Immunology of the Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose:   Methods:   Results: Elevated BMP6 was found in 63/80 (78.8%) of pSS patients examined in this study. In humans, ALK2 and ALK3 receptors…
  • Abstract Number: 1072 • 2015 ACR/ARHP Annual Meeting

    Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE

    Robert W Hoffman1, Joan T Merrill2, Marta E. Marta Alarcón Riquelme3, Michelle Petri4, Ernst R Dow5, Eric Nantz6, Laura K Nisenbaum5, Krista M Schroeder6, Wendy J Komocsar6, Narayanan B Perumal5, Matthew D Linnik6, Guilherme V Rocha6 and Richard E Higgs6, 1Immunology-Medical, Eli Lilly and Company, Indianapolis, IN, 2OMRF, Oklahoma, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, 5Eli Lilly and Company, Indiananpolis, IN, 6Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Elevated Type-I interferon (IFN) signature characterizes at least 50% of adults with SLE and has been associated with autoantibodies and more severe disease in…
  • Abstract Number: 1608 • 2013 ACR/ARHP Annual Meeting

    A Phase I Single-Dose Crossover Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy Of AMG 811 (anti-IFN-gamma) In Subjects With Discoid Lupus Erythematosus

    Victoria P. Werth1, David Fiorentino2, Stanley B. Cohen3, David Fivenson4, Chris Hansen5, Steve Zoog6, Greg Arnold7, Christine Wang8, Michael Boedigheimer6, Andrew Welcher6, James Chung6, Barbara Sullivan6 and David A. Martin9, 1Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA, 2Dermatology, Stanford University School of Medicine, Redwood City, CA, 3Metroplex Clinical Research Center, Dallas, TX, 4David Fivenson, MD, Dermatology, PLLC, Ann Arbor, MI, 5University of Utah School of Medicine, Salt Lake City, UT, 6Amgen, Thousand Oaks, CA, 7Medical Sciences, Amgen, Thousand Oaks, CA, 8Biostatistics, Amgen, Thousand Oaks, CA, 9Medical Sciences, Amgen, Seattle, WA

    Background/Purpose: Discoid Lupus Erythematosus (DLE) is the most common form of chronic cutaneous LE (CCLE) and develops in up to a quarter of SLE patients.…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology